We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hopes to Bring Iclusig to Front-Line Treatment Dashed For Now
Hopes to Bring Iclusig to Front-Line Treatment Dashed For Now
October 21, 2013
Ariad has pulled the plug on a key Phase III trial for its drug Iclusig that it had hoped would support front-line approval of the drug to treat blood cancer.